LITHIUM CARBONATE ( DrugBank: Lithium carbonate, Carbonate )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	10
13	多発性硬化症／視神経脊髄炎	1
17	多系統萎縮症	2
18	脊髄小脳変性症（多系統萎縮症を除く。）	2
127	前頭側頭葉変性症	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-000579-19-ES (EUCTR)	04/04/2022	02/11/2021	An international multi-center clinical trial to investigate the efficacy of multiple drug compounds in patients with Amyotrophic Lateral Sclrerosis (ALS).	A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) - MAGNET	Amyotrophic Lateral Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Lithium Carbonate INN or Proposed INN: Lithium carbonate Other descriptive name: LITHIUM CARBONATE	Stichting TRICALS Foundation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	171	Phase 3	Belgium;Spain;Ireland;Australia;Netherlands;United Kingdom;Sweden
2	EUCTR2020-000579-19-NL (EUCTR)	25/06/2021	29/03/2021	An international multi-center clinical trial to investigate the efficacy of multiple drug compounds in patients with Amyotrophic Lateral Sclrerosis (ALS).	A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) - MAGNET	Amyotrophic Lateral Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Lithium Carbonate INN or Proposed INN: Lithium carbonate Other descriptive name: LITHIUM CARBONATE	Stichting TRICALS Foundation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	171	Phase 3	Spain;Belgium;Ireland;Australia;Netherlands;United Kingdom;Sweden
3	EUCTR2008-006722-34-IT (EUCTR)	23/06/2009	11/12/2008	Multicentric randomized placebo controlled trial of Lithium carbonate combined with Riluzole in patients with ALS - RCT ALS Lithium	Multicentric randomized placebo controlled trial of Lithium carbonate combined with Riluzole in patients with ALS - RCT ALS Lithium	Amyotrophic Lateral Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis	Trade Name: CARBOLITHIUM INN or Proposed INN: Lithium	ISTITUTO SUPERIORE DI SANITA`	NULL	Not Recruiting			Female: yes Male: yes			Italy
4	EUCTR2008-006224-61-ES (EUCTR)	12/06/2009	04/05/2009	Ensayo clínico multicéntrico, aleatorizado, controlado para evaluar la eficacia del tratamiento con carbonato de litio en pacientes con Esclerosis Lateral Amiotrófica	Ensayo clínico multicéntrico, aleatorizado, controlado para evaluar la eficacia del tratamiento con carbonato de litio en pacientes con Esclerosis Lateral Amiotrófica	Esclerosis Lateral Amiotrófica MedDRA version: 9;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis	Trade Name: PLENUR INN or Proposed INN: LITIO CARBONATO Other descriptive name: LITHIUM CARBONATE	Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	NULL	Not Recruiting			Female: yes Male: yes			Spain
5	NCT00925847 (ClinicalTrials.gov)	June 2009	19/6/2009	Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis	Open Multicenter Study of Lithium in Patients With Amyotrophic Lateral Sclerosis LISLA	Amyotrophic Lateral Sclerosis	Drug: lithium	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	N/A	Both	23	Phase 2	France
6	EUCTR2008-005106-38-ES (EUCTR)	14/05/2009	26/02/2009	ENSAYO CLÍNICO RANDOMIZADO DOBLE CIEGO DE CARBONATO DE LITIO COMO TERAPIA DE ASOCIACIÓN EN ESCLEROSIS LATERAL AMIOTRÓFICA (FASE II) - LIELA	ENSAYO CLÍNICO RANDOMIZADO DOBLE CIEGO DE CARBONATO DE LITIO COMO TERAPIA DE ASOCIACIÓN EN ESCLEROSIS LATERAL AMIOTRÓFICA (FASE II) - LIELA	Esclerosis Lateral Amiotrofica MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis	Trade Name: PLENUR INN or Proposed INN: LITIO CARBONATO Other descriptive name: LITHIUM CARBONATE	Lucia Galan Hospital Clinico San Carlos	NULL	Not Recruiting			Female: yes Male: yes	280		Spain
7	EUCTR2008-006891-31-GB (EUCTR)	17/02/2009	28/07/2010	A randomised placebo-controlled trial of Lithium carbonate in Amyotrophic Lateral Sclerosis (LiCALS) - LiCALS	A randomised placebo-controlled trial of Lithium carbonate in Amyotrophic Lateral Sclerosis (LiCALS) - LiCALS	Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis	Trade Name: Lithium Apogepha Product Name: Lithium Carbonate Other descriptive name: LITHIUM CARBONATE Trade Name: Lithium Carbonate Product Name: Lithium Carbonate Other descriptive name: LITHIUM CARBONATE Trade Name: Lithium Citrate Product Name: Lithium Citrate Other descriptive name: LITHIUM CITRATE	King's College London	NULL	Not Recruiting			Female: yes Male: yes	220	Phase 4	United Kingdom
8	NCT00818389 (ClinicalTrials.gov)	January 2009	6/1/2009	Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)	A Multicenter, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Lithium in Combination With Riluzole in Volunteers With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: Lithium Carbonate;Drug: Riluzole;Drug: placebo	Massachusetts General Hospital	ALS Association;ALS Society of Canada;National Institute of Neurological Disorders and Stroke (NINDS);University of Toronto;State University of New York - Upstate Medical University;Columbia University;University of Kentucky	Terminated	18 Years	N/A	All	84	Phase 2/Phase 3	United States;Canada
9	EUCTR2008-002110-22-NL (EUCTR)	16/09/2008	05/08/2008	A randomised sequential trial of Lithium in amyotrophic lateral sclerosis - Lithium in ALS	A randomised sequential trial of Lithium in amyotrophic lateral sclerosis - Lithium in ALS	Amyotrophic lateral sclerosis (ALS) is a disease characterised by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS can occur at anytime in adulthood. Muscle weakness gradually progresses. Approximately 50% of patients die within 3 years after onset of symptoms, usually as the result of respiratory failure. To date, only one drug, i.e. riluzole, has proven to extend survival in patients with ALS, but only by approximately 3 to 6 months. MedDRA version: 9.1;Level: LLT;Classification code 10052889;Term: ALS	Trade Name: Lithiumcarbonaat 400 PCH tabletten Product Name: Lithiumcarbonaat Other descriptive name: LITHIUM CARBONATE	Prof. dr L.H. van den Berg, UMC-Utrecht	NULL	Not Recruiting			Female: yes Male: yes			Netherlands
10	NCT00790582 (ClinicalTrials.gov)	May 2008	12/11/2008	A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)	A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: lithium carbonate	Forbes Norris MDA/ALS Research Center	Muscular Dystrophy Association	Completed	21 Years	80 Years	All	109	Phase 2	United States

先頭へ

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01259388 (ClinicalTrials.gov)	May 2011	10/12/2010	A Pilot Study of Lithium in Progressive Multiple Sclerosis	A Pilot Trial of Lithium in Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Lithium Carbonate	VA Office of Research and Development	NULL	Completed	30 Years	65 Years	All	23	Phase 1/Phase 2	United States

17. 多系統萎縮症

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-016377-15-IT (EUCTR)	26/10/2009	26/10/2009	DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY - Lithium in MSA	DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY - Lithium in MSA	Muliple system atrophy MedDRA version: 9.1;Level: HLT;Classification code 10008028	Trade Name: LITIO CARBONATO INN or Proposed INN: LITHIUM CARBONATE	UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
2	NCT00997672 (ClinicalTrials.gov)	October 2009	16/10/2009	Lithium in Multiple System Atrophy	A Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess Efficacy, Safety and Tolerability of Lithium in Multiple System Atrophy.	Multiple System Atrophy	Drug: Lithium Carbonate;Drug: Placebo	Federico II University	NULL	Terminated	18 Years	80 Years	All	10	Phase 2	Italy

18. 脊髄小脳変性症（多系統萎縮症を除く。）

臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01096082 (ClinicalTrials.gov)	May 2011	29/3/2010	Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3	Randomized Clinical Trial to Assess the Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3	Spinocerebellar Ataxia Type 3;Machado Joseph Disease	Drug: Lithium Carbonate;Drug: Placebo	Hospital de Clinicas de Porto Alegre	NULL	Completed	16 Years	80 Years	Both	62	Phase 2/Phase 3	Brazil
2	NCT00683943 (ClinicalTrials.gov)	May 18, 2008	22/5/2008	Lithium Treatment for Patients With Spinocerebellar Ataxia Type I	Pilot Study of Tolerability of Lithium Therapy in Patients With Spinocerebellar Ataxia Type I (SCA1)	Spinocerebellar Ataxia Type I	Drug: Lithium Carbonate	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	18 Years	65 Years	All	13	Phase 1	United States

127. 前頭側頭葉変性症

臨床試験数 : 90 / 薬物数 : 87 - (DrugBank : 30) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 88

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02862210 (ClinicalTrials.gov)	January 27, 2017	7/8/2016	Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia	Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia	Frontotemporal Dementia (FTD)	Drug: Lithium Carbonate;Drug: Placebo	Columbia University	Alzheimer's Drug Discovery Foundation	Completed	40 Years	85 Years	All	17	Phase 2	United States

先頭へ